Company Plans to Leverage Current FDA Clinical Trial Clearance to Accelerate Entry into Chronic Obstructive Pulmonary Disease and Idiopathic Pulmonary Fibrosis

Therapeutic Solutions International announced today data demonstrating its JadiCell™ adult stem cell product induces multiplication of specific lung cells which are believed to give rise to new lung tissue which compensate for damaged cells.

In a series of experiments, lung injury was induced in mice by administration of inflammatory stimuli representative of bacterial infection, trauma, (TLR-4 agonists) or viral infection (TLR-3 agonists). Intravenous delivery of JadiCells resulted in preservation of lung function and increased multiplication of cells believed to be the “repair cells” of the lung. Importantly, depletion of T regulatory cells negated the therapeutic effects of the JadiCells.

“Based on my medical experience, the currently published data on the JadiCells, and what I have personally observed from administration under the Right to Try exemption, I believe that these cells represent a paradigm shift in the way we approach lung disease,” said Dr James Veltmeyer, Chief Medical Officer of the Company. “While we are currently focused on the imminent launch of our Multi-Nation Phase III COVID lung failure trial, we are leveraging existing data to address other lung diseases.”

The newly announced data supports previous patent filings covering the ability of JadiCell not only to prevent inflammation, cytokine storm, and lung injury, but also to stimulate existing lung stem cells to heal damage that has already occurred. Importantly, the observation that T regulatory cells appear to be essential in stimulation of lung healing suggests the possibility that JadiCells induce a long-term beneficial effect. In contrast to cells of the mesenchymal stem cell family, of which JadiCells are a part of, T regulatory cells have the ability to become memory cells which in many cases persist for life.

“The field of cell therapy is the future of medicine, however, in order to maximize their potential benefits, we need to always strive to learn as much about their science as possible,” said Dr. Thomas Ichim, Board Member of the Company. “TSOI in my opinion is unique because we follow the science instead of trying to force the science to fit in a narrative.”

“As we are finalizing preparations for initiation of our Phase III COVID-19 lung failure clinical trial, I am proud to report that significant basic scientific progress is being made, which is setting the foundation for possible expansion into COPD and IPF which represent a significant unmet medical need,” said Timothy Dixon President and CEO of the Company.

About Therapeutic Solutions International, Inc.

Therapeutic Solutions International is focused on immune modulation for the treatment of several specific diseases. The Company's corporate website is https://therapeuticsolutionsint.com, and our public forum is https://forum.therapeuticsolutionsint.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20220419005646/en/